Alembic Pharmaceuticals: Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Alembic Pharmaceuticals (APLLTD) filed a disclosure titled "Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)". The company is valued at about ₹17,822 crore.
What happened
Alembic Pharmaceuticals (APLLTD) filed a disclosure with the exchanges on 4 November 2026 at 09:59 PM titled "Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".
Company snapshot
Alembic Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹17,822 crore.
The stock last traded at ₹906.7, against a 52-week range of ₹635.8–₹998 (9.2% below the high).
Before this filing the shares had moved −1.5% over the month and −0.8% over three months. Average daily turnover over the last 20 sessions was about ₹8.65 crore.
Promoters held 69.87% at the end of Q2 FY27. Foreign institutions owned 4.55% and domestic institutions 15.43%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,711 | 154.4 | 7.85 |
| Q2 FY26 | 1,910 | 184.7 | 9.4 |
| Q3 FY26 | 1,876 | 133 | 6.76 |
| Q4 FY26 | 1,848 | 201.5 | 10.31 |
| Q1 FY27 | 2,150 | 173.1 | 8.8 |
What history shows
This is not the company's first approval disclosure: BCEIE has at least 12 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 1.4% on average the next trading day and was up 2.4% on average after five days (11 filings with price data).
Across 114 similar disclosures by other Healthcare companies, shares moved +0.4% on average the next day and +1.0% over five days; 51% of them rose the next day.
Market-wide, 1,582 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 30 Oct 2026 | Receives USFDA Final Approval for Venetoclax Tablets, 10 mg, 50 mg… | +0.6% | — |
| 27 Oct 2026 | Alembic Pharmaceuticals Limited receives USFDA Final Approval for… | +2.1% | +4.7% |
| 19 Oct 2026 | Herewith the Intimation under Regulation 30 of SEBI LODR… | −1.1% | −1.0% |
| 17 Oct 2026 | Alembic Pharmaceuticals Limited receives USFDA Final Approval for… | −0.2% | −2.9% |
| 16 Sept 2026 | Update on USFDA inspection conducted during 3rd March, 2025 to 7th… | +2.5% | +3.0% |
What to watch
- 4 November 2026: Board meeting — Financial Results/Other business matters.
In the news
Recent coverage elsewhere (links open the original publisher):
- Alembic Pharmaceuticals Limited Estimates – NSE:APLLTD
- Alembic Pharmaceuticals Q2 PAT rises 81% to Rs 335 crore
- Pradeep Jain Appointed Associate Vice President – Accounts & Finance at Alembic Pharmaceuticals
- Earnings call transcript: Alembic Pharmaceuticals jumps on raised FY 2027 outlook By Investing.com
- Alembic Pharmaceuticals Receives USFDA Approval for Venetoclax Tablets
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.